Page last updated: 2024-11-06

n-(hydroxymethyl)nicotinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

n-(hydroxymethyl)nicotinamide, also known as nicotinamide riboside (NR), is a naturally occurring nicotinamide derivative found in trace amounts in foods like milk, yeast, and some plants. It is a precursor to nicotinamide adenine dinucleotide (NAD+), a vital coenzyme involved in cellular energy production and various metabolic processes. NR has gained significant attention for its potential health benefits, particularly its ability to increase NAD+ levels in the body. Studies have shown that NR supplementation can enhance mitochondrial function, improve insulin sensitivity, protect against age-related decline, and promote longevity. The synthesis of NR involves the enzymatic reduction of nicotinamide mononucleotide (NMN) by the enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT). NR is being extensively studied for its therapeutic potential in a variety of diseases, including neurodegenerative disorders, metabolic diseases, and cancer. The ease of administration and its ability to bypass the rate-limiting step in NAD+ biosynthesis makes NR a promising candidate for therapeutic intervention.'

N-(hydroxymethyl)nicotinamide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID77116
CHEMBL ID92024
CHEBI ID134775
SCHEMBL ID352358
MeSH IDM0046210

Synonyms (90)

Synonym
smr001562101
MLS002695904
AC-6974
n-hydroxymethyl-nicotinamide
CHEMBL92024
SPECTRUM5_001885
1n1ygm997e ,
unii-1n1ygm997e
DIVK1C_006737
choligen
bilamid
cholamide (pyridine deriv.)
nicoform
nikomethamide
nicodine
isochol
n-(hydroxymethyl)-3-pyridinecarboxamide
nicotinsaeurehydroxymethylamid
nikoform
savatin
c 1094
nikodin
brn 0128633
einecs 222-668-4
3-pyridinecarboxylic acid hydroxymethylamide
nicotinamide, n-(hydroxymethyl)-
3-pyridinecarboxamide, n-(hydroxymethyl)-
bilizorin
bilocid
bidbilan
nicodin
n-(hydroxymethyl)nicotinamide
cholamid
coloton
SPECTRUM_000376
OPREA1_521547
BSPBIO_002767
OPREA1_687785
n-(hydroxymethyl)nicotinamide, 98%
NCGC00095786-01
KBIOSS_000856
KBIO1_001681
KBIOGR_001683
KBIO3_001987
KBIO2_005992
KBIO2_000856
KBIO2_003424
SPECTRUM3_001014
SPECTRUM2_001197
SPBIO_001273
SPECPLUS_000641
SPECTRUM4_001142
SPECTRUM2300137
NCGC00095786-02
CHEBI:134775
nikoform (tn)
D08051
3569-99-1
cholamid (tn)
hydroxymethylnicotinamide
inchi=1/c7h8n2o2/c10-5-9-7(11)6-2-1-3-8-4-6/h1-4,10h,5h2,(h,9,11)
jrfkioflcxkvot-uhfffaoysa-
H1001
n-(hydroxymethyl)pyridine-3-carboxamide
AKOS000121436
A6230
CCG-40316
nicometamide
nifoform
FT-0629289
S5390
hydroxymethylnicotinamide [who-dd]
n-(hydroxymethyl)nicotinamide [mi]
n-(hydroxymethyl)-nicotinamide
SCHEMBL352358
nicotinylmethylamide
W-106656
n-hydroxymethylnicotinamide
DTXSID20189205
mfcd00010437
AS-59855
nicotinylmethylamide,(s)
Q27252632
D90986
n-(hytroxymethy)micotinamide
HY-116993
SY051839
CS-0066962
EN300-18232
Z57472937
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridinecarboxamideA member of the class of pyridines that is a substituted pyridine in which at least one of the substituents is a carboxamide or N-substituted caraboxamide group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency3.98110.010039.53711,122.0200AID1479
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID227699Virtual screen for compounds with anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's1 (9.09)18.2507
2000's2 (18.18)29.6817
2010's5 (45.45)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.35 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]